BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cellect Biotechnology

Cellect Announces a Major Milestone for Enabling Stem Cells Production

By

Highlights

  • Successfully completes POC testing for first ever scalable production of ApoTainer™
  • Cellect’s ApoTainer™ built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost
  • Dr. Shai Yarkoni, Cellect CEO commented: “We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. Our ApoTainer™ is intended to ensure this demand is met with a cost-effective quality manufacturing of stem cells.”
  • The ApoTainer™ is covered by a portfolio of IP including a patent application for apoptotic selection of stem cells using FasL-coated magnetic beads

[Read more…]

Cellect Receives Israeli Ministry of Health Approval to Initiate Phase I/II Clinical Trial in Leukemia Patients

By

  • Company’s innovative cell selection product may dramatically reduce bone marrow transplantation risks
  • Patient enrollment expected to begin in the next few weeks 

TEL AVIV, Israel, Sept. 13, 2016 (GLOBE NEWSWIRE)—Cellect Biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that the Company has received the Israeli Ministry of Health’s approval to begin a Phase I/II clinical trial in leukemia patients. The trial, which Cellect expects will be initiated in a few weeks, is planned to be conducted in the bone marrow transplantation (“BMT”) unit of Rambam Hospital, and led by Clinical Assistant Professor, Zila Zuckerman, the Director of the unit. [Read more…]

BioInformant's World-Class Clients